Company intelligence / Profile preview
CK Cell Technologies
Castle Hill, New South Wales, Australiackcelltechnologies.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
CK Cell Technologies is developing innovative regenerative medicine products based on stem cell and exosome technologies. Their pipeline includes preclinical and early-stage clinical programs targeting wound healing, neurodegeneration, spinal cord injury, osteoarthritis, nerve and skin regeneration. They emphasize quality, safety, collaboration with clinicians/scientists, and translation of research into new therapeutic modalities. At least one clinical trial is underway or completed for their lead program(s).
- Therapeutic areas
- DermatologyRheumatologyNeurology
- Modalities
- Stem cell-derived products (including iPSC and MSC technologies)Exosomes (cell-free therapies)Tissue engineering
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on CK Cell Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CK Cell Technologies.